Perrigo Pharma Intl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PERRIGO PHARMA INTL
PERRIGO PHARMA INTL has nine approved drugs.
There is one tentative approval on PERRIGO PHARMA INTL drugs.
Drugs and US Patents for Perrigo Pharma Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo Pharma Intl | PREVACID 24 HR | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 022327-001 | May 18, 2009 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | LORATADINE AND PSEUDOEPHEDRINE SULFATE | loratadine; pseudoephedrine sulfate | TABLET, EXTENDED RELEASE;ORAL | 076050-001 | Jan 30, 2003 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | SPRAY, METERED;NASAL | 078104-001 | Jul 30, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | LORATADINE | loratadine | TABLET, CHEWABLE;ORAL | 210033-001 | Jun 12, 2019 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | LORATADINE | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 076011-001 | Sep 29, 2003 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | SPRAY, METERED;NASAL | 078104-002 | Nov 14, 2014 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Perrigo Pharma Intl | MINOXIDIL | minoxidil | AEROSOL, FOAM;TOPICAL | 091344-001 | Apr 28, 2011 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

